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ABSTRACT
Iyer, Ashvin M.S., Department of Pharmacology and Toxicology, Wright State
University, 2015. Developing Proteomic and Cytokine Biomarkers for Vulvodynia.

Vulvodynia is a chronic, heterogeneous, and multifactorial disease. This condition
may affect up to 18 percent of the female population including Caucasians, African
Americans, Africans and Hispanics particularly those sexually active at child bearing age.
The etiology of this condition is complex and multifactorial and it is frequently
accompanied by physical disabilities, psychological distress and sexual dysfunction.
Clinically, vulvodynia can be generalized or localized and pain can be provoked or
unprovoked. Patients may also describe vulvar paresthesias or dysesthesias that may last
hours. The International Society for the Study of Vulvar Disease (ISSVD) recognizes
vulvar pain related to a specific disorder (infectious, inflammatory, neoplastic or
neurologic) and vulvodynia (pain due to nonspecific etiology). In the case of vulvodynia,
even the basic biological processes involved in the condition are unclear and further
investigation of these processes is vital for constructing a substantive knowledge base.
While recent research activities have created a foundation and enhanced our knowledge
base, our understanding of the etiology and pathology of this condition is largely
incomplete. Reports suggest a strong link that vulvodynia initiates a strong inflammatory
reaction that is mediated by cytokines. In our study, we measured the levels of 27
cytokines that may be involved in this inflammatory response in the vaginal milieu of
vulvodynia patients. For our study, we received 15 vaginal swabs from patients
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diagnosed with vulvodynia and 5 vaginal swabs from healthy patients with no signs and
previous history of this disease. Also the application of 2D-Difference in Gel
Electrophoresis to study the presence and expression of different proteins in the vaginal
milieu of vulvodynia patients has shown promising results. Our results indicate a more
than 10-fold increase in IL-1ra levels (p<0.03), a 7-fold increase in IL-12 levels (p<0.04),
a 3-fold increase in PDGF-bb (p<0.04) levels, a 9-fold increase in VEGF levels (p<0.02)
and a 2-fold decrease in IL-17 levels in vulvodynia patients compared to healthy controls.
Our results indicate the presence of a strong inflammatory response involved in
vulvodynia. Our proteomic studies indicate alterations in the normal proteomic levels in
the vaginal milieu of vulvodynia patients compared to healthy controls.
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INTRODUCTION
Background
Vulvodynia is a common genital problem affecting the vulvar region in women. It
has been reported to occur in nearly 8% of women (Edwards 2015). Patients with this
disorder usually complain of vulvar discomfort which includes burning, and any
combination of stinging, irritation, itching, pain, rawness and dyspareunia (Masheb et al.
2000). This disorder has been recently recognized and is reported to affect 200,000
women in the United States (Goetsch 1991). This condition has been observed in all age
groups but mainly observed in women during their reproductive years. The development
of the disease can be acute or attained gradually (Burning Vulvar Syndrome 1984). The
symptoms associated with the condition can be constant or encountered intermittently
(Marinoff and Turner 1992). Quality of pain can be localized to a particular region in the
vulva or spread throughout the vulva and the pain can be sensed deep inside the vulva or
superficially (Lynch 1986). Pain suffered by such patients is usually moderate to severe
(Lynch 1986). Any actions that bring pressure to the vulva can aggravate the pain in this
condition (Friedrich 1987). Simple tasks like intercourse, insertion of tampons and
speculum, tight-clothing and activities like bicycling, horseback riding or even simple
exercises can aggravate the pain (Friedrich 1987).
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Subtypes of Vulvodynia
Vulvodynia is seen as the most difficult challenge faced by medical practitioners
dealing with vulvar disorders. Five subtypes of this condition have been reported (Table
1) (McKay 1988). The first subtype, vulvar dermatoses, includes diagnosis of lichen
sclerosis, lichen planus, chronic dermatitis and eczema (Masheb et al. 2000). Cyclic
candidiasis/vulvitis is the second subtype and includes diagnosis of repeated candida
infections. This stage can be confirmed by running a swab test for cultures which usually
occur during the menstrual cycle (Masheb et al. 2000). The third subtype, vulvar
papillomatovirus, includes the presence of a small papillae around the vestibule. Usually
this subtype has been observed to be present with human papillomatovirus (Masheb et al.
2000). The fourth subtype, essential vulvodynia, includes dysesthesia, caused by nerves
which bring discomfort similar to that seen in postherpatic neuralgia (Masheb et al.
2000). The fifth subtype, vulvar vestibulitis syndrome, includes discomfort and increased
sensitivity in the vulvar vestibule (Masheb et al. 2000). This subtype may have an
absence of physical findings with the exception of erythema (Masheb et al. 2000). This
classification is one of many and has not been used by many researchers in the field.
There is a lot of overlapping among the various classifications and a more accurate and
detailed classification is required (Masheb et al. 2000).
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Table 1: Diagnosis of Vulvodynia (Masheb et al. 2000)

Significance
International Society for the Study of Vulvar disease (ISSVD), in 1985
recognized vulvodynia syndrome (Itza et al. 2012). This condition is a common reason
for consultation among women. Patients first consult with their family physicians, then
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they seek help from gynecologists, dermatologists, neurologists or psychiatrists (Itza et
al. 2012). Patients end up visiting many doctors in search of a treatment making this
condition a very frustrating one. Associated with the disorder are anxiety, severe
depression and sexual dysfunction that further complicates the disease (Green and
Hetherton 2005).
There are several etiopathogenic theories for vulvodynia. Women mostly report vaginal
candidiasis as a condition suffered in their past (Itza et al. 2012). Reports suggested an
allergic contact sensitization of candida (Ramirez De Knott et al. 2005). Studies also
claimed that the disorder may be due to calcium oxalate crystals in the urine which may
cause the vulvar burning. But this hypothesis was later rejected (Harlow et al. 2008).
Demographics
Vulvodynia affects 200,000 women according to the New York Times.
Reports suggest that vulvodynia is found in Caucasians (Friedrich 1987; Furlonge et al.
1991; Mann et al. 1992; McCormack 1990; Peckham et al. 1986), African Americans
(Mann et al. 1992) and Hispanics (Friedrich 1987; Furlonge et al. 1991; Mann et al.
1992) but predominant in Caucasians. More than 65% of women who are suffering from
this disorder range between 20 to 40 years of age (Friedrich 1987). Vulvodynia has had a
significant burden to society, the health care industry, the patient suffering from this
disorder and her family (Sadownik 2014). The annual economic burden of vulvodynia
has been reported to be $31-$72 billion in the USA (Xie et al. 2012). This figure
represents all costs associated with direct and indirect health care costs (Sadownik 2014).
Many patients have to take leave from work which adds to the indirect costs (Sadownik
2014). Another problem is that most women do not seek medical attention when they are
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affected by the disease. They usually treat themselves by applying some creams and
lotions which tends to make the condition more severe. Patients with vulvodynia suffer
from depression (Schover, Youngs, Cannata 1992) and report to the reduction in the
quality of life (Arnold et al. 2006). Many women suffer with frustration (Nunns and
Mandal 1997), anxiety (Nunns and Mandal 1997), stress (Ehrstrom et al. 2009) and
severe depression (Schover, Youngs, Cannata 1992). This leads to decrease in sexual
activity and level of satisfaction achieved (Gates and Galask 2001; Sadownik 2000). The
pain associated with vulvodynia has a negative influence on the patient’s interpersonal
relationship (Sadownik 2014).
Anatomy of Vulva
The vulva is the female genital organ that is present externally. Oftentimes it is
confused with vagina. It basically comprises the labia minora, labia majora, clitoris, mons
pubis and the vestibule (Puppo 2011).
The vagina represents an internal genital organ. The urethrovaginal septum
separates the vagina from urethra. The vagina has no secretory glands present (Gray,
Williams and Bannister 1995; Testut and Latarjet 1972; Dickinson 1949). The
Bartholin’s gland is located at the ends of the vaginal wall (Gray, Williams and Bannister
1995; Testut and Latarjet 1972; Dickinson 1949). These glands have been reported to
secrete viscous secretions just before attaining peak sexual pleasure (Masters and
Johnson 1966). Endocrine cells have been found in the Bartholin’s gland that produce
serotonin, calcitonin, bombesin and katacalcin (Fetissof et al. 1989). Many mucus glands
open in to the vestibule called minor vestibular glands.
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The mons pubis is largely made up of adipose tissue. It’s a skin layer composed of
sebaceous glands and sweat glands and is almost entirely covered with pubic hair (Sokol
A and Shveiky D, 2008).
Labia Majora consists of two longitudinal folds that extends inferiorly and
posteriorly from the mons pubis. It consists of several glands and is covered with hair
(Gray, Williams and Bannister 1995; Testut and Latarjet 1972).
The labia minora represent two small cutaneous fold which range from 3-4 cm in
length (Puppo 2011). The two folds are very closely located and the labia minora in
general are unrecognizable (Puppo 2011). The upper parts converge together and form
the prepuce. The posterior parts converge and form frenulum (Gray, Williams and
Bannister 1995; Testut and Latarjet 1972; Dickinson 1949). Labia minora contain thick
erectile connective tissue that contain many small vascular networks for blood flow.
During sexual stimulation, this region becomes engorged with blood causing it to
increase in thickness up to three times (Puppo 2011; Shafik, Shafik, Ahmed 2004; Yang
et al. 2006).
The clitoris is the primary female sex organ. It is extensively supplied with nerve
endings. The crura, body and glans make up the clitoris (Gray, Williams and Bannister
1995; Testut and Latarjet 1972; Dickinson 1949). They basically are made of spongy
tissues which become rigid during coitus (Gray, Williams and Bannister 1995; Masters
and Johnson 1966; Testut and Latarjet 1972; Dickinson 1949; Yang et al. 2006).
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Figure 1: Vulval Anatomy (courtesy of the Vulval Pain Society)

Management of Vulvodynia
General Vulvar Care
First step is to eradicate the contact of all potential irritants which may take the
form of creams (O'Hare and Sherertz 2000). Other commonly applied products like
fragrances, sanitary products, cleansing gels and douches and products containing alcohol
should be prohibited (O'Hare and Sherertz 2000; Segal 2008). Application of ice or cold
gel packs to the vulva has been found to be helpful in alleviating the pain (Segal 2008).
Regular cleaning of vulva with mild soap or an emollient with no preservatives can be
applied to bring in moisture to the skin and improve its protective function (Haefner et al.
2005) . The above-mentioned remedies have not been used successfully in the treatment
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of moderate to severe conditions of vulvodynia (Davis and Hutchison 1999), suggesting
only prevention of symptoms.
Topical Therapies
Application of 5% lidocaine ointment every night for a period of 6 months
resulted in improvement in the ability of women to have intercourse (Zolnoun, Hartmann,
Steege 2003). It is thought to inhibit the feedback transmission of pain (Zolnoun,
Hartmann, Steege 2003). Lidocaine 2% or 5% in the form of jelly or an ointment can be
applied prior to sexual intercourse (Segal 2008).
Clinical trials have reported capsaicin to have a protective effect on the
inflammatory and neurologic disorders that are commonly seen in patients with
vulvodynia (Fugh-Berman 2003). Capsaicin is reported to cause a desensitization
reaction which is carried out by neuropeptides, involving substance P (Steinberg et al.
2005). Other agents include nitroglycerin cream which seems to provide temporary relief
from dyspareunia (Walsh et al. 2002) and amitryptiline 2% with baclofen cream 2%
(Nyirjesy 2009).
Oral Therapies
Tricyclic antidepressant are a popular choice for the treatment of neuropathic pain
associated with vulvodynia (Segal 2008). Amitriptyline is the first line treatment initiated
on low doses and slowly increasing the dose up to 150 mg per week (Haefner et al.
2005). Common side effects associated with its regimen include sedation, weakness,
dizziness, lethargy, dry mouth and palpitations (Segal 2008). Another class of drugs, the
selective serotonin reuptake inhibitors (SSRIs) have been included in the regimen for
treatment of vulvodynia (Edwards 2003). Patients who do not respond to tricyclic
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antidepressant are switched over to gabapentin treatment (Segal 2008). Gabapentin is a
well-known anticonvulsant and has been effective in controlling neuropathic pain (Segal
2008). Several weeks of dosing are required to reach maximum efficacy. Gabapentin has
fewer side effects compared to the tricyclic antidepressants (Segal 2008). Carbamazepine
is another anticonvulsant drug that can be used in case of patients not responding to
gabapentin (Haefner et al. 2005).
Physical Therapy
Changes brought to the pelvic floor muscles, which may accompany pelvic floor
tone, instability of these muscles resulting in loss of muscular control are usually
associated with chronic vulvodynia (Sadownik 2014). Physical therapy educates patients
on their pelvic floor muscles, increasing their potential to gain control of these muscles in
order to contract, and relax completely, and address muscle spasms (Sadownik 2014).
Three simple exercises are currently employed by gynecologists in order to counsel
patients with vulvar pain. Kegel’s maneuver, reverse Kegel’s maneuver and superficial
perineal massage (Sadownik 2014). Patients are encouraged to follow these exercises up
to 10 sets in a day (Sadownik 2014).
Surgical Options
Surgery is usually reserved for patients who are non-responsive to conventional
treatments. Surgery can be divided into local excision, vestibuloplasty and total
vestibulectomy (Masheb et al. 2000). Based on the extent of vestibular involvement, the
excision should be tailored to the individual patients (Davis and Hutchison 1999).
It is important that patients first be subjected to a cotton swab test which helps in locating
areas of the vestibule experiencing pain and which may need to be surgically removed
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(Masheb et al. 2000). Local excision involves locating the problem areas and removing
the affected tissue in an elliptic manner. (Haefner et al. 2005). Vestibuloplasty involves
excision of the anterior, posterior or lateral vestibule without the involvement of the
vagina (Haefner 2000). Vestibulectomy involves cutting of the complete vestibule from
the urethra including the hymen (Masheb et al. 2000). It is the most popular choice of
surgery for women with provoked vulvodynia (Masheb et al. 2000). Success rate range
from 60% to 94% after this surgery (Davis and Hutchison 1999). The drawbacks of this
surgery are the cost and risks associated with the removal of glands that function to
lubricate. Scarring of tissues during surgery is another drawback that is seen with this
type of surgery (Masheb et al. 2000).
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Figure 2: Management of Chronic Vulval burning (Helen E. Lotery et al, 2004)
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Role of Cytokines in Inflammation
Cytokines are small glycoproteins produced by various cells but mostly helper T
cells and macrophages (Zhang and An 2007). They are associated with the regulation of
immunity, inflammation and hematopoiesis (Khan 2008). These mediators are involved
in promoting the proliferation and differentiation of hematopoietic cells and in regulation
and determining the nature of the immune response (Thèze 1999). Each cytokine has
several effects on different types of cells. Interactions exist between different cytokines
and can be synergistic or inhibitory (Thèze 1999). Cytokines induce their actions by
binding to specific receptors on the cell surface. The target cells respond by new mRNA
and protein synthesis that results in the specific biological response (Khan 2008). When a
peripheral nerve injury takes place, macrophages and Schwann cells accumulate at the
injury site and secrete cytokines and other mediators for repair (Zhang and An 2007).
Pro-inflammatory cytokines participate in the up-regulation of inflammation
(Zhang and An 2007). The main cytokines of this category are TNFα, IL-1, IL-6, IL-8
and macrophage inflammatory protein-1α (Jaffer, Wade, Gourlay 2010). The presence of
these cytokines have been reported to be involved in many injuries (Halter et al. 2005;
Mokart et al. 2002). Anti-inflammatory cytokines suppress the actions of proinflammatory cytokines. IL-1ra, IL-10 and IL-13 constitute the major anti-inflammatory
cytokines (Jaffer, Wade, Gourlay 2010; Zhang and An 2007). Among them, IL-10 is the
most potent and inhibits the expressions of TNF-α, IL-6, and IL-1 (Zhang and An 2007).
IL-10 has the property of inducing anti-inflammatory cytokines and inhibiting proinflammatory cytokines (Zhang and An 2007). A study reported that low blood levels of
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anti-inflammatory cytokines IL-10 and IL-4 was associated with patients with chronic
pain (Uceyler et al. 2006).
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  

Figure 3: Response to insult (Jaffer, Wade, Gourlay 2010)
Seckin-Alac et al. (2014) compared the levels of TNF-α, IL-1β and IL-1 receptor
in women with vulvar vestibulitis syndrome with control patients. They found a
significant difference in TNF-α. Positive staining has been found in 40% of the VVS
samples and in 7.7% of the samples from the control group. Their intention was to
suggest that the local inflammation may be mediated by cytokines in VVS patients.
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Clinical and research studies have reported vulvodynia patients to have low
serological levels of interleukin-1 receptor antagonist which might suggest such patients
to be exposed to a greater risk of a pro-inflammatory immune response as a result of their
inability to terminate IL-1 production during an inflammatory reaction (Gerber et al.
2002). Studies have shown women with vulvodynia to have a higher frequency of alleles
in IL-1B and IL-1 receptor polymorphic genes (Gerber et al. 2002; Jeremias, Ledger,
Witkin 2000).
Foster et al. (2007) conducted a study where they challenged VVS patients with
candida albicans (yeast) and alpha-melanocyte-stimulating hormone in-vitro. They found
that coincubation with α-MSH plus yeast resulted in significant 3-fold increase in IL-6
and more than 40-fold increase in IL-8 in VVS patients and controls. Vestibular
fibroblasts from VVS patients produced high levels of IL-1β, IL-6 and IL-8 at baseline
and following yeast-alone challenge.
Introduction to 2D-Difference Gel Electrophoresis  
2D Fluorescence Difference Gel Electrophoresis (2D-DIGE) is an advanced
method for labeling of proteins that make use of CyDye Fluors. They utilize the principle
of 2-Dimensional gel electrophoresis. This technology simplifies the process of detecting
and identifying proteins using the 2-D electrophoresis and allows up to three different
proteins samples to be analyzed on the same gel.
The three different protein samples are labelled with different CyDyes. Usually
the control samples are labelled with Cy5, the treated or diseased samples are labelled
with Cy3 and an internal standard consisting of a mix of all the control and treated
samples are labelled with Cy2. After labelling of samples, they are pooled together and
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are subjected to the first dimensional separation based on the isoelectric points and
subsequent second dimensional separation based on molecular weight using the SDS
PAGE gels.
The advantage of this technique is that it allows multiplexing different samples to
the same first and second dimensional separation that helps limit experimental variation.
The individual samples are then visualized independently using individual excitation and
emission wavelengths for each CyDye. Another advantage of this technique is that by
running multiple samples on a single gel, the number of gels required to produce the
same data is reduced. The internal standard represents all proteins from every sample that
is present on all the gels. This increases the confidence of matching between gels and
allows the generation of accurate spot statistics between gels.
The CyDye Fluors are dyes that have a reactive NHS ester group. In the presence
of a protein sample, they covalently bind through an amide linkage to the epsilon amino
group of lysine of the protein sample. Cy3, Cy5 and Cy2 dyes are matched for size and
charge so that the three labelled protein samples are subjected to the same 2-D gel
electrophoresis separation.
Application of 2D-DIGE for Biomarker discovery
Grubbs et al., (2015) successfully labelled porcine serum using the 2D-DIGE
methodology and proved that the serum can be used for biomarker discovery. Yu, Rustgi,
and Blair (2005) used this approach to identify biomarkers for pancreatic cancer. They
utilized serum samples from patients with pancreatic cancer and depleted the serum of
the abundantly found proteins and successfully labelled with CyDyes.
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Huang et al. (2006) also utilized this technique and identified an increased
expression of transferrin in the serum of patients with breast cancer. Dutta et al. (2015)
investigated serum proteins of patients with endometriosis using 2D-DIGE and compared
the results with healthy control patients using MALDI-TOF/TOF MS. This analysis
resulted in 25 significant different proteins. They concluded that haptoglobin (HP), Ig
kappa chain C region (IGKC), alpha-1B-glycoprotein (A1BG) can be considered
effective serum protein diagnostic markers for different stages of endometriosis.
In a study using interleukin 10 knockout mice, circulating proteins from serum
samples were identified from different age groups of mice to detect biomarkers for
inflammatory bowel disease. Fifteen different proteins were identified by 2D-DIGE and
MALDI-TOF/TOF mass spectrometry in comparison with non-inflamed mice. The
identified proteins were confirmed by ELISA and western blots (Viennois et al. 2015).
Huang et al. (2014) reported transthyretin, retinol binding protein 4, haptoglobin,
clusterin, serum amyloid A protein, apolipoprotein A-I, apolipoprotein C-III and
apolipoprotein C-II to be expressed in significantly different levels in patients with
Occupational medicamentosa-like dermatitis induced by trichloroethylene compared to
healthy controls. They identified these proteins by 2D-DIGE and MALDI-TOF MS/MS
and confirmed them by western blots.
2D-DIGE was successfully used to identify seventeen different proteins among
patients with normal but non-fertilizing sperm and patients with normal fertilization.
Twelve proteins were identified by mass spectrometry and they found two proteins,
laminin receptor LR67 and L-xylulose reductase which may influence gametes
interaction (Frapsauce et al. 2014). Wu et al. (2014) identified glucose-regulated protein
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78, glutathione s-transferase pi, apolipoprotein AI, alpha-1 antitrypsin and gastrokine-1 in
gastric cancer tissues obtained from surgery by 2D-DIGE and confirmed them by western
blots.
Preliminary Studies  
My team is currently working in 3 areas
1) A double-blinded study was done where vaginal samples were assessed for bacterial
flora, cytokine and proteomic analysis. Samples were obtained from patients between
days 22 and 28 of their menstrual period, with no previous sexual intercourse for 3
days and on no medications or contraceptives. This pool of 17 patients was divided
into three groups; i) symptomatic patients with vulvodynia, ii) patients with
vulvodynia in remission and iii) patients with no history of vulvodynia which were
used as controls for the study. The study showed that all 17 patients had a negative
culture for fungi and were negative by PCR for Atoprobium, Megasphera and
Leptorichia.
Preliminary data obtained from Microbiological studies are very promising.
Patient samples used as controls showed the presence of L.Crispatus which was not
found to be present in patients affected with symptomatic vulvodynia or in remission.
Symptomatic patients and patients in remission showed the presence of L. Gassery. L
Iners was found to be present in both controls and vulvodynia samples and was found
not to play any role in the disease. These results suggest the presence of an alteration
in the vaginal flora in patients with vulvodynia. From our analysis, we found
differences in lactobacillus species. As the study was done in small sample
population, it is difficult to say that these results would be consistent to the major
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population with this disease. Reports suggest that all L. Crispatus and 71% of L.
Gassery produce hydrogen peroxide. L. Crispatus promotes in pregnant patients the
stability of the normal microflora and L. Gassery and L Iners are more conductive to
the occurrence of abnormal vaginal flora (Verstraelen et al. 2009).
2) Cytokine analysis was performed on 13 samples with 6 controls and 7 patients with
vulvodynia. We utilized the Bio-plex bead based system which assayed 27 different
cytokines in these patient samples. Patients with vulvodynia showed an increase of
nearly 35 times interleukin-17 (IL-17) compared to control patients. Also these
patients showed a 7 fold decrease in macrophage inflammatory protein 1 beta (MipIb) and a 3-fold decrease in Interleukin-12 (IL-12) compared to control patients. This
preliminary results suggest the involvement of an immunological response involving
candida in patients with vulvodynia.
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Table 2: Cytokine analysis of vulvosecretions in vulvodynia	
  
3) The data regarding proteomic analysis via MALDI-TOF mass spectrometry is not
significant although it suggests a tendency to demonstrate a difference between
patient with vulvodynia and controls. Our preliminary sample was small and some
samples were not adequate for this type of analysis, lessening the quality of our data.
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A larger population of samples will ensure adequate sample numbers to provide
meaningful data.
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HYPOTHESIS
Vulvodynia has been found to be a highly prevalent, chronic and multifactorial
disease. Our preliminary studies have created a strong scientific base by enhancing our
knowledge about this condition. Therefore a strong understanding of the etiology and
pathology of this condition is vital to draw further conclusions.
I hypothesize that:
•

Vulvodynia may involve an alteration in the balance of cytokines and proteins
expressed in the vaginal milieu that maintains an inflammatory response.

My hypotheses will be tested by using a multidisciplinary approach including:
proteomics and cytokines evaluation of the vaginal milieu. Samples will be obtained from
patients who are suffering from vulvodynia and with patients with no history of
vulvodynia which will be used as controls for the study.
I will evaluate the following:
•

Types of cytokines present in patients with this condition

•

The presence of any atypical proteins in the vaginal milieu of patients with this
condition.
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Specific Aims

Specific Aim 1: To Identify and characterize cytokines present in patients with this
condition
Inflammatory reactions have been previously described that strongly suggest a
correlation with the change in bacterial infections. The goal of this aim is to determine on
a more extensive level, changes in cytokines that may be involved in this inflammatory
reaction. Previous studies have focused only on specific cytokines. In contrast, we
propose to use a multiplexed bead-based system to simultaneously examine 27 cytokines
at from each sample. Preliminary studies indicate that our method of collection, i.e., a
swab used to collect the secretions dipped into a collection tube containing PBS and
media, is adequate to analyze cytokines in this manner. Protein measurements were
generally in the upper range of the standard curve indicating plenty of protein was
acquired. The goal is to establish evidence of cytokines to fulfill the RFA request to
“Identify and validate biomarkers that may be used to diagnose disease, predict disease
development or progression, and stratify patient subsets or response to therapy, including
biomarkers at the molecular, gene/protein and cell level.”
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Specific Aim 2: The vaginal milieu respond to the insult by changes in proteins and/or
abnormal protein production
To more fully understand the changes in the vaginal milieu, a more complete
profile of the non-bacterial and non-cytokine proteins and other macromolecules should
be obtained. Mass spectrometry is a commonly employed technique to achieve this as it
is more sensitive and can provide specific protein/peptide identification via direct
sequencing. The goal of this aim is develop a proteomic profile for normal versus
vulvodynia patient secretions. Following this, protein/peptide sequencing will be done to
attempt identification of unique proteins/peptides.
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MATERIALS AND METHODS
	
  

Strategy
The protocol for all Specific Aims will include the following visits:
Exhaustive history and comprehensive assessment of environmental factors,
topical vulvovaginal irritants and co morbid conditions acknowledged in the exclusion
criteria. Additionally, psychosocial contributing factors, daily stressors, pain assessment
other associated symptoms including previous sexual experiences and current sexual
activity.
Detailed physical and pelvic examination samples will be obtained for
proteomics, cytokines, vaginal lactobacillus and facultative anaerobic bacterial flora
analysis from vaginal secretions and we will procure specimens for vaginal fungal
cultures.
The above described protocol could be schematically divided in 4 parts:
I.

diagnosis-confirmation of vulvodynia, by history and physical examination: the
diagnostic approach is currently utilized by most researchers including our team

II.

exclusion of co morbid conditions that could interfere with the protocol

III.

exclusion of fungal and facultative anaerobic bacteria infections

IV.

analyzing the role that proteomics and cytokines play in vulvodynia
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Inclusion Criteria
The patient group will consist of women ages 12 to 60 suspected or currently
diagnosed with vulvodynia, or previously diagnosed and currently symptomatic. The
control group was composed of asymptomatic and otherwise healthy women with no
previous history of any chronic or recurrent vulvovaginal condition matched to the study
group for age, race and parity. The control samples were obtained from patients who
attend our collaborator’s clinic for their regular check-ups. Patients were explained about
the study and the ones ready to participate gave their informed consent and agreed to sign
and follow the protocol.
Exclusion criteria
Patients were excluded from the study under the following protocols:
I.

Aged under 12 and above 60 years old.

II.

Undergoing surgical treatment for vulvodynia or other vaginal complications or who
are currently on therapy or in remission from vulvodynia.

III.

Diagnosed with medical conditions like cancer or a condition that is not under control
like diabetes mellitus, hypertension, collagen disease, hemoglobinopathy, renal
insufficiency and others.

IV.

Having Neurological or psychiatric complications including post-traumatic stress
disorder and alcohol and/or drug addiction.

V.

Patients who have chronic pain conditions including fibromyalgia, levator ani
syndrome, pelvic floor tension myalgia, interstitial cystitis, endometriosis and
irritable bowel syndrome.

VI.

	
  

Pregnant patients
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VII.
VIII.

	
  

Patients unable to follow the protocol.
Patients with interstitial cystitis.
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Experimental Design

Figure 4: Experimental Design
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Sample Collection
Samples were collected in the form of Vaginal Swabs by our collaborating
Obstetrics and Gynecological Physicians who have experience with diagnosis and
treatment of Vulvodynia. Patients visiting their clinic for the treatment and regular checkups were used for sample collection under an approved IRB. Vaginal swabs from 15
patients showing active symptoms of vulvodynia were collected and 5 vaginal swabs
from patients showing no symptoms of vulvodynia were used as control for the study.
Samples were received and stored at -80°C.
Cytokine Analysis
Bio-plex Pro cytokine assay are essentially multiplex immunoassays which make
use of magnetic beads to couple the biomarker of interest. This technique is a slight
modification of the sandwich ELISA. The antibodies are covalently linked to the beads
and bind to the biomarker of interest when treated with the sample. These beads are then
washed repeatedly to remove excess protein and a detection antibody is added that binds
to the primary antibody, thus completing the sandwich complex. Streptavidinphycoerythrin conjugate is then added to serve as a fluorescent indicator.
The 96-well plate from the Human Cytokine Kit is first wetted with Assay buffer,
Beads solution is then added to the respective wells and washed twice with wash buffer.
Samples and controls (50 µl) are loaded into the wells and analyzed in duplicate. The
plate is kept for some time for incubation and is washed three times with wash buffer.
Detection antibody is added to the wells and incubated for 30 minutes at room
temperature. Streptavidin-phycoerythrin conjugate is then added to the wells and
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subjected to three washes with wash buffer. The plate is scanned on the Bioplex 200
instrument and statistics computed using One way ANOVA.
Trichloroacetic acid (TCA) precipitation of proteins
	
  

Five vulvodynia samples were selected from the pool of 15 samples based on the
highest amount of protein content for 2D-DIGE analysis. The protein content was
determined using Bradford’s test. All five controls were used for this analysis. 200
microliters of vaginal specimen samples and controls was taken into a new
microcentrifuge tube. 20 microliters of TCA was added to the samples and controls. The
tubes were placed on ice for at least one hour to precipitate proteins. The tubes were then
centrifuged and the pellet was rinsed with acid acetone (39 parts acetone: 1 part
hydrochloric acid). The tubes were centrifuged and the pellet was resuspended in
sufficient lysis buffer (8M Urea, 30 mM Tris and 4% CHAPS) to ensure complete
solubilization of the pellet. The pH of this solution was adjusted between 8.5- 9.0 with
dilute sodium hydroxide. The pH was checked using a pH paper by spotting 2 microliters
of the sample. An internal standard was created using 100 µl of vulvodynia sample and
100 µl of control samples that were to be analyzed on the same 2D gel and were treated
in a similar manner.
DIGE Labelling of Samples  
Vulvodynia samples (20 µl) were labelled with 1µl of Cy3 dye. 20 µl of each
control samples was labelled with 1 µl of Cy5 dye and 20 µl of the pooled samples was
labelled with 1ul of Cy2 dye. The tubes were centrifuged for a brief period and kept on
ice for 30 minutes in the dark following which 1µl of 10mM lysine was added to stop the
labelling reaction. The tubes were kept on ice for 10 minutes. To each tube, 20 µl of 2X
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sample buffer was added (Urea 8M, CHAPS 2%, DTT 2%) and kept on ice for 10
minutes. The three tubes were then pooled into a single microcentrifuge tube.
Rehydration buffer (74µl of 8M Urea, 2% CHAPS, 50mM dithiothreitol, 0.2% w/v Biolyte® 3/10 ampholytes and trace amounts of bromophenol blue) was added to the pooled
tube.

Figure 5: DIGE labeling of samples
Rehydration of Immobilized pH Gradient (IPG) Strips
Biorad ReadyStrip™ IPG strips 11 centimeters, pH 3-10 was rehydrated using
active reabsorption technique. The channel of the focusing tray was loaded with 200 µl of
the labelled pooled sample and the strip was faced gel side down to facilitate absorption
of the sample into the gel. After one hour, 2 mls of mineral oil was added to the channel
to prevent evaporation of the sample and the focusing tray was placed on the PROTEAN
IEF Cell. Rehydration was done under active settings at 50V overnight (11-16 hours).
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Isoelectric Focusing and SDS-PAGE
Wicks were wetted with 6 µl of nanopure water. The ends of the gel were lifted to
place the wetted wick so that it covered the electrode. Wicks are important in absorbing
salts and other contaminants that may interfere with first dimensional separation.
Isoelectric focusing was performed under recommended settings in the manual of the
Biorad ReadyStrip™ IPG strips. After the run, the strips were held vertically to drain the
mineral oil and placed on rehydration trays gel side up. 4 µl of Equilibration buffer 1 (6M
Urea, 2%SDS, 0.375 TRIS-HCl pH 8.8, 20% glycerol and 2% w/v DTT was added to the
channel in which the strips were placed and the tray was shaken in the orbital shaker for
45 minutes. This buffer was then poured out and 4 mls of Equilibration buffer 2 (6M
Urea, 2% SDS, 0.375 M Tris-HCl pH 8.8, 0.5g Iodoacetamide and 20% glycerol) was
added and similarly shaken for 30 minutes. The strips were then rinsed with 1X running
buffer and sealed with overlay agarose (0.5% agarose, 25mM Tris, 192mM glycine, 0.1%
SDS and trace of bromophenol blue) in the well of BIORAD CRITERION GEL.
BIORAD Precision Plus Protein™ Dual Extra Standards Was used as ladder to mark the
progress of the gel run.
Imaging
The gels were scanned using 488nm wavelength for Cy2, 532 nm for Cy3 and
635 nm for Cy5. To facilitate visualization of spots the brightness was adjusted
accordingly.
Spot picking
Selected spots were obtained using a gel cutter and placed in a microcentrifuge
tube and stored at -80° C.
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RESULTS

Cytokine analysis of vulvodynia secretions
Vaginal secretions from 15 vulvodynia patients and 5 control patients were subjected to
cytokine analysis using the Bio-Rad Bio-Plex Human Cytokine Assay. Overall, 27
cytokines were assayed and the standard curves for each of them were generated during
the same run.
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Figure 6: Standard Curve of Interleukin-1ra
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Hu IL-12(p70) (75)
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Figure 7: Standard Curve of Interleukin-12 levels	
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Figure 8: Standard Curve of VEGF levels	
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Table 3: Cytokine Evaluation of Vulvodynia Patients
Control
Vulvodynia
Cytokine
Mean ± SEM
Mean ± SEM
(pg/ml)
(pg/ml)
IL-1b
IL-1ra
IL-2
IL-4
IL-5
IL-6
IL-7
IL-8
IL-9
IL-10
IL-12
IL-13
IL-15
IL-17
Eotaxin
FGF basic
G-CSF
GM-CSF
IFN-g
IP-10
MCP-1(MCAF)
MIP-1a
PDGF-bb
MIP-1b
RANTES
TNF-a
VEGF

83.12 ± 72.65
9557.49 ± 30292.92
5.37 ± 6.05
0.79 ± 0.56
1.15 ± 1.86
1.70 ± 1.56
3.31 ± 5.85
985.72 ± 512.48
6.93 ± 4.82
28.16 ± 30.46
31.13 ± 74.07
5.34 ± 12.62
OOR<
98.22 ± 21.16
9.32 ± 8.25
116.59 ± 54.27
40.10 ± 64.44
334.43 ± 221.05
15.21 ± 19.03
190.45 ± 304.18
33.83 ± 41.55
4.21 ± 1.28
17.60 ± 16.72
49.23 ± 25.10
103.72 ± 33.20
13.33 ± 10.22
133.38 ± 345.94

103.78 ± 41.94
96845.95 ± 17489.63
13.85 ± 3.50
1.57 ± 0.32
3.64 ± 1.07
5.28 ± 0.90
13.98 ± 3.38
862.93 ± 295.88
15.64 ± 2.78
96.94 ± 17.59
228.28 ± 42.76
34.07 ± 7.29
2.37 ± 1.48
45.61 ± 12.22
22.90 ± 4.76
158.35 ± 31.33
147.71 ± 37.20
615.05 ± 127.62
45.42 ± 10.98
391.70 ± 175.61
99.24 ± 23.99
3.20 ± 0.74
62.29 ± 9.65
54.87 ± 14.49
52.39 ± 19.16
20.33 ± 5.90
1244.69 ± 199.73

P- Value

Change

0.808
0.023
0.241
0.242
0.263
0.063
0.132
0.838
0.136
0.066
0.033
0.064
0.045
0.171
0.514
0.165
0.286
0.186
0.574
0.190
0.502
0.032
0.848
0.197
0.560
0.012

Increase
Increase
Increase
Increase
Increase
Increase
Increase
Decrease
Increase
Increase
Increase
Increase
Increase
Decrease
Increase
Increase
Increase
Increase
Increase
Increase
Increase
Decrease
Increase
Increase
Decrease
Increase
Increase

	
  

Significant differences in the levels of IL-1ra, IL-12, IL-17, PDGF-bb and VEGF
was seen between patients with vulvodynia and controls. IL-1ra showed more than 10fold increase in vulvodynia samples compared to control samples (p<0.03). At the same
time, vulvodynia patients demonstrated a 7-fold increase in IL-12 (p<0.04), a 3-fold
increase in PDGF-bb (p<0.04) and a 9-fold increase in VEGF (p<0.02) compared to
control patients. Also a 2-fold decrease in the levels of IL-17 (p<0.05) was observed in
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vulvodynia patients compared to control patients. IL-15 which was not detected in
control patients was observed to be up-regulated in vulvodynia patients.

Figure 9: IL-1ra levels in vulvodynia and control patients. The bars represent mean ±
SEM of IL-1ra levels.
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Figure 10: IL-12 levels in vulvodynia and control patients. The bars represent mean ±
SEM of IL-12 levels.

Figure 11: IL-17 levels in vulvodynia and control patients. The bars represent mean ±
SEM of IL-17 levels.
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Figure 12: PDGF-bb levels in vulvodynia and control patients. The bars represent mean ±
SEM of PDGF-bb levels.

Figure 13: VEGF levels in vulvodynia and control patients. The bars represent mean ±
SEM of VEGF levels. .
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2D-DIGE Results
Cytokine analysis provided an expanded view of specific inflammatory proteins
in vulvodynia. However, it is limited to the known quantity and type analyzed by the
BioPlex kit. To delve deeper into protein changes in vulvodynia, we chose to use 2DDIGE analysis of the proteins in the samples. In this method, proteins from disease and
treated samples can be differentially labeled with a fluorescent dye prior to running on
2D-Gels. Due to the costs involved and limitations in the control patient samples, we
chose to run 5 vulvodynia patient samples against 5 control patient samples by 2D-DIGE.
The gels were examined by fluorescence imaging at wavelengths to excite CY2, CY3,
and Cy5 dyes attached to the proteins. The samples were precipitated with TCA to
concentrate them further. We found that there was a unique pattern associated with the
samples from each group (Figure 4, 5, 6). A number of proteins were found to be
different between the groups, with some overlapping. A map of each unique protein
position was generated, printed and the unique spots pulled from each gel. These spots
were then digested with trypsin, cleaned up on C18 ZipTips. We are currently awaiting
sequencing by LC/MS.
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Figure 14: 2D-DIGE labeled vulvodynia and control samples. Control (Green) and
vulvodynia samples (Red) were labeled, mixed, and separated by isoelectric point (pH 310) in the first dimension and size in the second dimension.
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Figure 15: 2D-DIGE Individual Cy3 and Cy5 labelled samples. Unique spots were
marked using PDQuest software (Bio-Rad).
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Figure 16: 2D-DIGE Spot Identification. Unique spots were marked using PDQuest
software (Bio-Rad) and a protein map generated that was used to direct spot picking.
More than 130 gel spots were cut from the gels in this manner.
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DISCUSSION
	
  

Vulvodynia is a major health problem in the US; as many as 13 million women
may suffer from this condition that can lead to morbidity and a reduced quality of life for
many women. Vulvodynia is a clinical condition with various poorly defined antecedents.
Patients frequently experience: dyspareunia, chronic vulvar irritation, burning, and pain.
Some women identify the pain and increased sensitivity as generalized or localized that
can be provoked or occur spontaneously (two common diagnostic vulvodynia subtypes:
vulvar vestibulitis and vestibulodynia). The experience of chronic pain can consist of a
complex interaction of biological, behavioral, sociocultural, and environmental factors.
The basic biological process involved in the complexity of this condition is unclear and
investigation of such processes involved is vital for constructing a substantive knowledge
base. Recent research activities have created the foundation and enhanced our knowledge
base, our understanding of the etiology and pathology of this condition is largely
incomplete.
What we have learned from published literature that we can certainly exclude in
the etiology of vulvodynia is that it is a purely psychological disorder (Boardman and
Stockdale 2009; Bohm-Starke 2010) or a direct link to Human Papilloma Virus
(Graziottin and Serafini 2009; Gunter et al. 1998). It has been reported there is an initial
inflammatory response (Bohm-Starke 2010) which may result in peripheral and central
pain sensitization; mucosal nerve fiber proliferation, hypertrophy, hyperplasia and
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enhanced systemic pain perception have been reported (Leclair et al. 2011). One of the
biochemical mediators of inflammation is cytokines (Omoigui 2007). In women suffering
from vulvodynia, the genetic profile includes polymorphisms in genes coding for
cytokines, for IL-1 receptor antagonist, for IL-1 beta, and for mannose-binding lectin
(MBL) (Gerber, Witkin, Stucki 2008). It is possible that specific proteins could be
involved in the etiology of vulvodynia. Female hormones may be significant based on
recent reports of an increased progesterone receptor nuclear immunostaining and estrogen
receptor alpha expression (Leclair et al. 2011). It is also possible that hormonal changes
in addition to cytokines and specific proteins may serve as the causing agent for altering
the vaginal flora in vulvodynia.
The intent of our project was to develop new translational research strategies
designed to enhance our understanding of the etiology and underlying pathophysiology of
vulvodynia. Our hypothesis was that vulvodynia in part elicits an inflammatory reaction
that is represented by elevated levels of cytokines. To prove this, we utilized the Bio-Rad
Human Cytokine Group 1 Panel that allows us to quantify the levels of 27-different
cytokines. In our analysis, we found significant differences among 5 different cytokines
between the vulvodynia specimens and control specimens. These are IL-1ra, IL-12, IL17, PDGF-bb and VEGF. The most marked difference was seen in IL-1ra which showed
more than 10-fold increase, followed by VEGF that showed a 9-fold increase, followed
by IL-12 that showed a 7-fold increase and PDGF-bb that showed a 3-fold increase in
vulvodynia patients compared to healthy controls. Also a 2-fold decrease in the levels of
IL-17 was observed in vulvodynia patients compared to healthy controls. Another
interesting observation was seen in the levels of IL-15 which was not detected in control
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patients but was observed to be up-regulated in vulvodynia patients. These results suggest
the involvement of cytokines as a mediator for inflammation in vulvodynia patients. This
mediation involves both pro-inflammatory and anti-inflammatory cytokines. The balance
between them is crucial in determining the extent of the inflammatory reaction.
High levels of IL-1 has been shown to be involved in the development of many
inflammatory and autoimmune diseases of various organs such as joints, gastrointestinal
tract, central nervous system and blood vessels (Arend 2002). It is considered to be a
prototypic pro-inflammatory cytokine which upregulates the inflammatory reaction
(Merhisoussi et al. 2005). IL-1ra is a natural antagonist of IL-1 receptor inhibiting the
activity of IL-1α and IL-1β.It is well known from published literature that levels of IL-1ra
is elevated in patients with various inflammatory, pathogenic and post-surgical conditions
(Arend et al. 1998). To functionally inhibit the effects of IL-1, it is recommended for IL1ra levels to be at least 100-fold greater over IL-1 (Arend et al. 1990). Therefore the
balance between these two cytokines is important in determining the extent of the
inflammatory reaction. Studies utilizing animal models of diseases such as arthritis,
inflammatory bowel disease, kidney disease, infectious diseases and many more have
shown that either over-production of IL-1 and/or under-production of IL-1ra predisposes
to the development of such diseases (Arend 2002). Clinical trials recommend therapeutic
administration of IL-ra to overcome the damaging actions of IL-1. IL-1ra is approved in
the treatment of rheumatoid arthritis and can be helpful in other inflammatory diseases
(Gabay 2002; Hoffman and Patel 2004). Our study shows a significant increase in the
level of IL-1ra in vulvodynia patients suggesting a strong response to an inflammatory
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reaction which may be mediated by IL-1. This increase in IL-1ra in such patients may
explain the observed low levels of IL-1 in the vulvodynia patients.
IL-12 has been reported to function both as a pro-inflammatory cytokine as well
as a key immunoregulatory molecule. Its pro-inflammatory actions include the induction
of interferon gamma by T and natural killer cells and enhancing phagocytic and
bacteriocidal activity of phagocytic cells (Trinchieri 1998). It is also reported to be
involved in the release of other pro-inflammatory cytokines. Its production during the
primary phase of infection and inflammation favors differentiation and function of T
helper type 1 (Th1) cells and inhibiting the differentiation of T helper type 2 cells (Th2)
thereby ensuing antigen-specific immune response (Trinchieri 1998). In our analysis, an
increase in IFN-γ was seen in vulvodynia patients although this increase was not
significant. This increase can be attributed to the increased levels of IL-12. Significant
increase in IL-12 levels in vulvodynia patients clearly suggest the involvement of an
inflammatory response to this condition.
IL-17 is a key pro-inflammatory cytokine reported to contribute to several
inflammatory and autoimmune diseases (Baeten and Kuchroo 2013). Key products of IL17 are the T helper 17 cells (Th17) as well as cells from the innate immune system such
as mast cells and neutrophils (Moran et al. 2011; Kenna and Brown 2012). It induces the
expression of other pro-inflammatory cytokine, chemokines, growth factors and other
secondary mediators in target cells (Xu and Cao 2010). The detection of decreased levels
of this cytokine in vulvodynia patients suggests that IL-17 may be acted upon by other
mediators involved in the defense mechanism.
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Vascular endothelial growth factor (VEGF) and Platelet-derived growth factor
(PDGF) are proteins that play an important role in cell growth and division. Both are
involved in angiogenesis. Overexpression of VEGF is a contributing factor in the
development of disease, mostly seen in cancer. The role of VEGF has been identified in a
large number of disease processes ranging from cancer to autoimmunity, retinopathy, and
many more (Kieran, Kalluri and Cho 2012). The function of these growth factors are to
repair the damaged tissue. High levels of these seen in vulvodynia may suggest damage
of local tissue during the inflammatory reaction.
Hence our analysis can confirm that there is a presence of a strong inflammatory
reaction in vulvodynia patients. This reaction first involves the pro-inflammatory
cytokines which promotes systemic inflammation followed by the action of antiinflammatory cytokines which tries to negate the damaging effects of the former.
We are the first group to utilize the 2D-DIGE technology for proteomic studies in
vaginal specimens from vulvodynia patients and control patients. This technology allows
us to run the vulvodynia sample and the control sample together in one single run thereby
minimizing the gel to gel run variation and also reducing the number of gels required to
carry out the analysis. In our study we found different spots in the gel between the
vulvodynia patients and control patients which suggest there is a change in the proteomic
environment in the vulva of vulvodynia patients compared to healthy patients. Some
protein spots were specifically observed in vulvodynia patients which may indicate
presence of unique and novel proteins in such patients. These spots were identified and
were prepared for sequencing analysis by LC-MS. We are currently awaiting the results
of the sequencing analysis to help identify what proteins may be involved in this disease.
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Identification of such proteins can be useful in identifying markers for detection and
therapy.
Limitations of this study includes the use of a small sample size in our analysis.
We acquired 15 vaginal specimens from vulvodynia patients and 5 vaginal specimens
from healthy control patients. However, the results obtained from our cytokine analysis
shows clear significance in the level of 5 cytokines and rules out the possibility of it
being due to chance and the presence of any false-positive results. Another limitation
includes that the control vaginal specimens were stored in a nutrient liquid containing
albumin, which was absent in vulvodynia specimens. This may mask various proteins in
the 2D-DIGE analysis of control patients, which may interfere with the interpretation of
our results. The proteomic studies were limited to 5 gels due to the sample size of control
patients. These 5 samples were paired with vulvodynia samples containing the highest
protein content and subjected to 2D-DIGE analysis. This ignores the proteomic studies of
the remaining 10 vulvodynia samples in large part due to the cost of the 2D DIGE and
cleanup kits required to work with more samples.
Our future plans include to step up this study in a larger number of patients. As
we know vulvodynia has various causes, having a larger sample size will allow us to
group patients according to their causes and link them with characteristics such as age,
race, smoking status, drinking addiction, drug addiction like cocaine users and many such
groups. Also it would be interesting to perform longitudinal studies whereby patients are
observed from the time of diagnosis and monitored throughout the remainder of their
therapy. Carrying out timely studies of such patients and checking the levels of cytokines
can be helpful in determining valid biomarkers for vulvodynia.
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APPENDIX
Reagents and Materials
Serial	
  No	
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9	
  
10	
  
11	
  
12	
  
13	
  
14	
  
15	
  
16	
  
17	
  
18	
  
19	
  
20	
  
21	
  
22	
  

	
  

Name	
  
Amersham™	
  DIGE	
  Fluor,	
  
minimal	
  labelling	
  Kit	
  
(2nmol)	
  
Readystrip™	
  IPG	
  Strips	
  
ReadyPrep™	
  2-‐D	
  Starter	
  
Kit	
  
Criterion™TGX™	
  Precast	
  
Gels	
  
Mineral	
  Oil	
  
N,N,-‐Dimethyl	
  
Formamaide	
  
Lysine	
  
Trichloroacetic	
  acid	
  
Human	
  Cytokine	
  Assay	
  
Methanol	
  
Acetonitrile	
  
Criterion	
  Gel™	
  Blotting	
  
Sandwiches	
  
Albumin,	
  from	
  bovine	
  
serum	
  
Acetone	
  
	
  Precision	
  Plus	
  Protein	
  
Dual	
  Xtra	
  Standards	
  	
  
Ammonium	
  Bicarbonate	
  
CHAPS	
  
Glycine	
  
TRIS	
  
SDS	
  
Trypsin	
  from	
  porcine	
  
pancreas	
  
Sodium	
  Hydroxide	
  	
  

Company	
  
GE	
  Healthcare	
  

Catalogue	
  No.	
  
28-‐9345-‐30	
  

BIO-‐RAD	
  
BIO-‐RAD	
  

163-‐2014	
  
163-‐2105	
  

BIO-‐RAD	
  

567-‐1121	
  

BIO-‐RAD	
  
Fisher	
  Scientific	
  

163-‐2129	
  
D119-‐4	
  

SIGMA	
  
Fisher	
  Scientific	
  
BIO-‐RAD	
  
Fisher	
  Scientific	
  
Fisher	
  Scientific	
  
BIO-‐RAD	
  

L-‐5626	
  
A322-‐500	
  
M50-‐0KCAF0Y	
  
A412-‐4	
  
A955-‐4	
  
162-‐0239	
  

SIGMA	
  Life	
  
Science	
  
Fisher	
  Scientific	
  	
  
Bio-‐Rad	
  
Laboratories	
  Inc.	
  	
  
Fisher	
  Scientific	
  	
  
PIERCE	
  
Fisher	
  Scientific	
  	
  
Fisher	
  Scientific	
  	
  
BIO-‐RAD	
  
SIGMA-‐ALDRICH	
  

A2153-‐50G	
  

Fisher	
  Scientific	
  	
  

S318-‐3	
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A949-‐4	
  
161-‐0377	
  	
  
A643-‐500	
  
28300	
  
G46-‐500	
  
BP152-‐500	
  
161-‐0302	
  
T6567	
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